组蛋白去乙酰化酶抑制剂的抗肿瘤作用

摘要/Abstract

摘要：组蛋白去乙酰化酶（HDAC）是一类蛋白酶，对染色体的结构修饰和基因表达调控发挥着重要的作用。其在癌细胞中的过量表达引起乙酰化失衡，与肿瘤的发生有着密切联系。随着表观遗传学研究的深入，组蛋白去乙酰化酶抑制剂（HDACi）作为抗肿瘤药物，其高效性和低毒性得到了广泛的认可，相信会为肿瘤的治疗带来更多的突破。

肖洒,李玲,张明智. 组蛋白去乙酰化酶抑制剂的抗肿瘤作用[J]. 国际肿瘤学杂志, 2017, 44(10): 754-757.

Xiao Sa, Li Ling, Zhang Mingzhi. Antitumor effect of histone deacetylase inhibitors[J]. Journal of International Oncology, 2017, 44(10): 754-757.

［1］ Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis［J］. J Mol Biol, 2004, 338(1): 1731. DOI: 10.1016/j.jmb.2004.02.006. ［2］ Deacetylases H. Characterization of the classical HDAC family［J］. Biochem J, 2003, 370(Pt 3): 737749. ［3］ Lakshmaiah KC, Jacob LA, Aparna S, et al. Epigenetic therapy of cancer with histone deacetylase inhibitors［J］. J Cancer Res Ther, 2014, 10(3): 469478. DOI: 10.4103/09731482.137937. ［4］ Koeneke E, Witt O, Oehme I. HDAC family members intertwined in the regulation of autophagy: a druggable vulnerability in aggressive tumor entities［J］. Cells, 2015, 4(2): 135168. DOI: 10.3390/cells4020135. ［5］ Olsen EA, Kim YH, Kuzel TM, et al. Phase Ⅱb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous Tcell lymphoma［J］. J Clin Oncol, 2007, 25(21): 31093115. DOI: 10.1200/JCO.2006.10.2434. ［6］ Damaskos C, Karatzas T, Nikolidakis L, et al. Inhibitors: current evidence for therapeutic activities in pancreatic cancer［J］. Anticancer Res, 2015, 35(6): 31293135. ［7］ Takashina T, Kinoshita I, Kikuchi J, et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for nonsmallcell lung cancer cells［J］. Cancer Sci, 2016, 107(7): 955962. DOI: 10.1111/cas.12957. ［8］ Shin DY, Kim SJ, Yoon DH, et al. Results of a phase Ⅱ study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis［J］. Cancer Chemother Pharmacol, 2016, 77(4): 865873. DOI: 10.1007/s002800163005y. ［9］ Pili R, Liu G, Chintala S, et al. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clearcell renal cell carcinoma: a multicentre, singlearm phase Ⅰ/Ⅱ clinical trial［J］. Br J Cancer, 2017, 116(7): 874883. DOI: 10.1038/bjc.2017.33. ［10］ Pera B, Tang T, Marullo R, et al. Combinatorial epigenetic therapy in diffuse large B cell lymphoma preclinical models and patients［J］. Clin Epigenetics, 2016, 8: 79. DOI: 10.1186/s131480160245y. ［11］ Holkova B, Kmieciak M, Bose P, et al. Phase 1 trial of carfilzomib (PR171) in combination with vorinostat (SAHA) in patients with relapsed or refractory Bcell lymphomas［J］. Leuk Lymphoma, 2016, 57(3): 635643. DOI: 10.3109/10428194.2015.1075019. ［12］ Angelika Ihle M, MerkelbachBruse S, Hartmann W, et al. HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat［J］. J Pathol Clin Res, 2016, 2(2): 5971. DOI: 10.1002/cjp2.35. ［13］ Gu R, Liu T, Zhu X, et al. Development and validation of a sensitive HPLCMS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application［J］. J Chromatogr B Analyt Technol Biomed Life Sci, 2015, 1000: 181186. DOI: 10.1016/j.jchromb.2015.07.001. ［14］ Hu X, Wang L, Lin L, et al. A phase Ⅰ trial of an oral subtypeselective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced nonsmall cell lung cancer［J］. Chin J Cancer Res, 2016, 28(4): 444451. DOI: 10.21147/j.issn.10009604.2016.04.08. ［15］ Zhao S, Guo J, Zhao Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling［J］. Am J Transl Res, 2016, 8(7): 31693178. ［16］ Liu L, Qiu S, Liu Y, et al. Chidamide and 5flurouracil show a synergistic antitumor effect on human colon cancer xenografts in nude mice［J］. Neoplasma, 2016, 63(2): 193200. DOI: 10.4149/203_150422N214. ［17］ Lee HZ, Kwitkowski VE, Del Valle PL, et al. FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral Tcell lymphoma［J］. Clin Cancer Res, 2015, 21(12): 26662670. DOI: 10.1158/10780432.CCR143119. ［18］ O′Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral Tcell lymphoma: results of the pivotal phase Ⅱ BELIEF (CLN19) study. J Clin Oncol, 2015, 33(23): 24922499. DOI: 10.1200/JCO.2014.59.2782. ［19］ O′connor OA, Zullo K, Marchi E, et al. Targeting epigenetic operations with HDAC inhibitor and hypomethylating drugs in combination exhibit synergy in preclinical and clinical experiences in drug resistant Tcell lymphoma (TCL): a translational focus on doublet development［J］. Blood, 2015, 126(23): 109120. ［20］ Havas AP, Rodrigues KB, Bhakta A, et al. Belinostat and vincristine demonstrate mutually synergistic cytotoxicity associated with mitotic arrest and inhibition of polyploidy in a preclinical model of aggressive diffuse large B cell lymphoma［J］. Cancer Biol Ther, 2016, 17(12): 12401252. DOI: 10.1080/15384047.2016.1250046. ［21］ To KK, Tong WS, Fu LW. Reversal of Platinum drug resistance by the histone deacetylase inhibitor belinostat［J］. Lung Cancer, 2017, 103: 5865. DOI: 10.1016/j.lungcan.2016.11.019. ［22］ SanMiguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind phase 3 trial［J］. Lancet Oncol, 2014, 15(11): 11951206. DOI: 10.1016/S14702045(14)704401. ［23］ Richardson PG, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment［J］. Blood, 2016, 127(6): 713721. DOI: 10.1182/blood201509665018. ［24］ Shi W, Palmer JD, WernerWasik M, et al. Phase Ⅰ trial of panobinostat and fractionated stereotactic reirradiation therapy for recurrent high grade gliomas［J］. J Neurooncol, 2016, 127(3): 535539. DOI: 10.1007/s1106001620593. ［25］ Tan WW, Allred JB, MorenoAspitia A, et al. Phase Ⅰ study of panobinostat (LBH589) and letrozole in postmenopausal metastatic breast cancer patients［J］. Clin Breast Cancer, 2016, 16(2): 8286. DOI: 10.1016/j.clbc.2015.11.003. ［26］ Coiffier B, Pro B, Prince HM, et al. Results from a pivotal, openlabel, phase Ⅱ study of romidepsin in relapsed or refractory peripheral Tcell lymphoma after prior systemic therapy［J］. J Clin Oncol, 2012, 30(6): 631636. DOI: 10.1200/JCO.2011.37.4223. ［27］ Foss F, Horwitz S, Pro B, et al. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial［J］. J Hematol Oncol, 2016, 9(1): 22. DOI: 10.1186/s1304501602438. ［28］ Pellegrini C, Dodero A, Chiappella A, et al. A phase Ⅱ study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral Tcell lymphoma patients［J］. J Hematol Oncol, 2016, 9(1): 38. DOI: 10.1186/s1304501602661.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

组蛋白去乙酰化酶抑制剂的抗肿瘤作用

Antitumor effect of histone deacetylase inhibitors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价